Evaluating the effects of magnesium in colistin nephrotoxicity
Phase 3
Recruiting
- Conditions
- Acute Kidney Injury.Acute kidney failure, unspecifiedN17.9
- Registration Number
- IRCT20130917014693N15
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 96
Inclusion Criteria
Patients with indication of colistin therapy
patients with GFR> 60ml/min
patients with magnesium blood level between 1.9 and 3 mg/dl
Exclusion Criteria
patients younger than 18 years
patients with GFR< 60ml/min
patients with magnesium blood level of less than 1.9 or more than 3 mg/dl
Pregnant patients
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Acute Kidney Injury occurrence. Timepoint: Daily during the first week of colistin therapy. Method of measurement: The Kidney Disease Improving Global Outcomes (KDIGO) criteria for Acute Kidney Injury.
- Secondary Outcome Measures
Name Time Method Escalation or de-escalation of therapy. Timepoint: Daily during the first week of colistin therapy. Method of measurement: Colistin daily dose observation.;Length of hospitalization. Timepoint: At the time of discharge. Method of measurement: Counting the number of days.;Death. Timepoint: Daily. Method of measurement: Records Observation.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie magnesium sulphate's protective effects against colistin-induced nephrotoxicity?
How does intravenous magnesium sulphate compare to standard-of-care treatments in preventing acute kidney injury from colistin?
Are there specific biomarkers that predict susceptibility to colistin-induced nephrotoxicity in patients receiving magnesium sulphate?
What are the potential adverse events associated with magnesium sulphate administration in the context of colistin therapy, and how can they be managed?
What combination therapies or alternative compounds are being explored alongside magnesium to mitigate colistin-induced acute kidney injury?